Inozyme Pharma Inc., a Delaware-based company, has announced new compensation terms in light of its recent merger agreement with BioMarin Pharmaceutical, Inc. As part of the agreement, Inozyme's Board of Directors has approved transaction bonuses for key executives. Chief Financial Officer and Head of Business Development, Mr. Sanjay Subramanian, is set to receive a cash bonus of $350,000, while Dr. Matthew Winton, the Senior Vice President and Chief Operating Officer, will be awarded $320,000. These bonuses will be issued following the completion of the merger, contingent upon their continued employment until the closing date, with payments to be made within 30 days thereafter.